

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-3. (cancelled).

4. (original) A compound that is

3-(3-bromobenzyl)-11-methyl-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3,11-bis(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

11-acetyl-3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (currently amended) A pharmaceutical composition which is comprised of a compound in accordance with Claim ~~1~~ 21 and a pharmaceutically acceptable carrier.

6-8. (cancelled).

9. (currently amended) A method of treating or preventing a PK-related disorder, wherein the PK-related disorder is an IGF-1R-related disorder selected from: cancer, diabetes, a hyperproliferation disorder, and acromegaly in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim ~~1~~ 21.

10. (cancelled).

11. (currently amended) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim ~~1~~ 21.

12. (currently amended) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim ~~4~~ 21.

13. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~4~~ 21 in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) an angiogenesis inhibitor.

14. (original) The method of Claim 13, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

15. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~4~~ 21 in combination with radiation therapy.

16. (original) The method of Claim 15 wherein radiation therapy is also administered.


17. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~4~~ 21 and paclitaxel or trastuzumab.

18. (currently amended) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~4~~ 21 and a GPIIb/IIIa antagonist.

19. (original) The method of Claim 18 wherein the GPIIb/IIIa antagonist is tirofiban.

20. (currently amended) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim ~~1~~ 21 in combination with a COX-2 inhibitor.

21. (new) A compound of Formula I



wherein:

R¹ is independently selected from

- 1) H,
- 2) halo,
- 3) OR⁴,
- 4) NO₂,
- 5) -S(O)_mR⁴,
- 6) CN
- 7) unsubstituted or substituted C₁-C₁₀ alkyl,
- 8) unsubstituted or substituted aryl,
- 9) unsubstituted or substituted C₂-C₆ alkenyl,
- 10) unsubstituted or substituted C₃-C₁₀ cycloalkyl,
- 11) unsubstituted or substituted C₂-C₆ alkynyl,
- 12) unsubstituted or substituted heterocycle,
- 13) -C(O)R⁴,
- 14) C(O)OR⁴,
- 15) C(O)N(R⁴)₂,

16) $S(O)_mN(R^4)_2$, and

17) $N(R^4)_2$;

R^2 is selected from

- 1) H,
- 2) C_1 - C_6 alkyl, and
- 3) $(C=O)C_1$ - C_6 alkyl,

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

R^3 is

- 1) C_1 - C_6 alkyl

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

R^4 is independently selected from

- 1) H,
- 2) unsubstituted or substituted C_1 - C_{10} alkyl,
- 3) unsubstituted or substituted C_3 - C_{10} cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) unsubstituted or substituted heterocycle, and
- 6) CF_3 ;

m is independently 0, 1 or 2;

s is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.